Leipzig University

Running trials

• Not yet recruiting

  A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

  NCT07335562· Phase 3· Juno Therapeutics, Inc., a Bristol-Myers Squibb Company· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Recruiting

  Efficacy of Asciminib in Chronic Phase CML Patients With T315I Mutations

  NCT07789574· Phase 2· Thomas Ernst, Prof. Dr. med.· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.

  2026-525367-40-00· Phase 3· AstraZeneca AB· Source

• Not yet recruiting

  A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity

  NCT07861100· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07465289· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

  NCT07719348· Phase 1/2· Servier· Source

• Recruiting

  A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.

  2025-523285-25-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)

  2025-525016-41-00· Phase 2· AstraZeneca AB· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Bicara Therapeutics· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

  NCT07775300· Phase 3· Eli Lilly and Company· Source

• Recruiting

  BGB-43395 in Combination with Letrozole versus CDK4/6i with Letrozole for Patients with Previously Untreated Advanced or Metastatic HR+/HER2- Breast Cancer

  NCT07492641· Phase 3· BeOne Medicines I GmbH· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

  2025-523815-12-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Recruiting

  Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.

  NCT07843927· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial

  2025-524078-40-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  PREFer

  NCT06916416· Phase 2· University Of Cologne· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis

  NCT07463521· Phase 3· UCB Biopharma SRL· Source

• Not yet recruiting

  A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma

  2025-524014-29-00· Phase 3· AstraZeneca AB· Source

• Recruiting

  A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

  NCT07549412· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

  2025-522440-41-00· Phase 2· Bluefin Biomedicine Inc.· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( RAINFOL-03 )

  2024-519818-31-01· Phase 3· Genmab A/S· Source

• Recruiting

  A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

  NCT07355218· Phase 3· EMD Serono Research & Development Institute, Inc.· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Recruiting

  A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

  NCT07409272· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· AstraZeneca· Source

• Recruiting

  Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

  NCT06875128· Phase 2· Delcath Systems Inc.· Source

• Recruiting

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

  NCT07216703· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

  NCT07325292· Phase 3· Sanofi· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

  NCT07218809· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

  NCT07277660· Phase 2· UCB Biopharma SRL· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· Phase 4· Medizinische Hochschule Hannover· Source

• Recruiting

  STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease

  NCT07280585· Phase 3· University of Cologne· Source

• Recruiting

  A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

  NCT07221188· Phase 3· GlaxoSmithKline· Source

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension

  NCT06804161· Phase 3· Prof. Dr. med. Ingo Eitel· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  NCT07211958· Phase 3· Syndax Pharmaceuticals· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033

  2024-520409-38-00· Phase 1· First Tracks Biotherapeutics Inc.· Source

• Recruiting

  A Phase II, Open-Label, Single-Center, Single-Arm Pilot Study to Evaluate the Safety, Tolerability and Efficacy of Blinatumomab for Treatment of Patients with Autoimmune B-Cell driven Diseases including Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc) and Granulomatous Polyangiitis (GPA), BlinA-B trial

  2025-523061-22-00· Phase 2· Universitaet Leipzig· Source

Showing 50 of 222.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers18 recruiting
• Acute myeloid leukaemia10 recruiting
• Myelodysplastic syndromes8 recruiting
• Colorectal cancer7 recruiting
• Multiple myeloma7 recruiting
• Gastric and oesophageal cancer6 recruiting
• Head and neck cancer6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Chronic myeloid leukaemia5 recruiting
• Endometrial cancer5 recruiting
• Liver and biliary tract cancer5 recruiting
• Lung cancer5 recruiting
• Metastatic breast cancer5 recruiting
• Ovarian cancer5 recruiting
• Cervical cancer4 recruiting
• Depression4 recruiting
• Melanoma4 recruiting
• Multiple sclerosis4 recruiting
• Pancreatic cancer4 recruiting
• Sarcoma4 recruiting
• Chronic lymphocytic leukaemia3 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Lupus (SLE)3 recruiting
• Myasthenia gravis3 recruiting
• Parkinson disease3 recruiting
• Stroke3 recruiting
• Chronic spontaneous urticaria2 recruiting
• Coeliac disease2 recruiting
• Glioblastoma2 recruiting
• Heart failure2 recruiting
• Hidradenitis suppurativa2 recruiting
• Myeloproliferative neoplasms2 recruiting
• Obesity2 recruiting
• Polycystic kidney disease2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Triple-negative breast cancer2 recruiting
• Alzheimer disease1 recruiting
• Amyloidosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Brain metastases1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Diabetic eye disease1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Eosinophilic oesophagitis1 recruiting
• Follicular lymphoma1 recruiting
• High blood pressure1 recruiting
• HIV1 recruiting
• Hodgkin lymphoma1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Myocarditis1 recruiting
• Neuroblastoma1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Active, not recruiting

  An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps

  NCT07424144· Phase 3· Sanofi· Source

• Completed

  Essentiale® liquid once-daily Phase III study

  2025-521678-32-00· Phase 3· Opella Healthcare Group S.A.S.· Source

• Completed

  A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperactivity Disorder

  NCT07001475· Phase 1· Boehringer Ingelheim· Source

• Active, not recruiting

  Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)

  2024-517818-15-00· Phase 1/2· Merck Healthcare KGaA· Source

• Completed

  A Phase 2b Study to Assess the Safety and tolerability of Batoclimab in Patients with CIDP

  2024-518364-12-00· Phase 2· Immunovant Sciences GmbH· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Active, not recruiting

  RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

  NCT06243458· Phase 2· GCP-Service International West GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

  2023-506185-31-00· Phase 2/3· Pliant Therapeutics Inc.· Source

• Completed

  Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

  NCT06430671· Phase 1· Cellerys AG· Source

• Active, not recruiting

  Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06082167· Phase 2/3· Exelixis· Source

• Completed

  A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1

  NCT05870748· Phase 2· Sutro Biopharma Inc.· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  Study of IMG-007 in Participants with Moderate to Severe Atopic Dermatitis

  NCT05984784· Phase 1/2· Inmagene LLC· Source

• Completed

  A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS).

  NCT05975905· Phase 2· Keros Therapeutics Inc.· Source

• Terminated

  A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

  NCT06220669· Phase 2· Eli Lilly and Company· Source

• Completed

  A Trial to Investigate TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

  2023-506092-10-00· Phase 2· Ascendis Pharma Oncology Division A/S· Source

• Completed

  A Phase 3 Study to Evaluate the Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

  2023-509472-42-00· Phase 3· Celgene International II S.a.r.l.· Source

• Terminated

  IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack

  NCT06139328· Phase 2· Boehringer Ingelheim· Source

• Completed

  CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax

  2023-505828-58-00· Phase 1· Curis Inc.· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS

  2023-503802-35-00· Phase 3· Vanda Pharmaceuticals Inc.· Source

• Completed

  Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy

  2022-500897-32-00· Phase 3· Cannaxan GmbH· Source

• Completed

  Virtual Interactive 3D Modelling to Improve Outcomes in Robotic-Assisted Partial Nephrectomy

  NCT06056505· University of Leipzig· Source

• Completed

  A Study to Investigate MBS2320 Patients with IPF

  2023-504418-30-00· Phase 2· Modern Biosciences Limited· Source

• Active, not recruiting

  Phase 2 Placebo-controlled Study to Assess the Safety, Efficacy, and PK of ESK-001 in SLE

  2022-502105-15-00· Phase 2· Alumis Inc.· Source

• Completed

  Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

  2022-502040-13-00· Phase 2· University of Leipzig· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· LEO Pharma· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Clinical trial of MK-7648A in adults and children with skin cancer

  NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria

  NCT05936567· Phase 2· Incyte Corporation· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  Phase 2b Study to Assess Efficacy and Safety of Batoclimab in Adult Participants with Active CIDP.

  2024-512646-42-00· Phase 2· Immunovant Sciences GmbH· Source

• Terminated

  Hidradenitis Suppurativa Study of Izokibep

  NCT05905783· Phase 3· ACELYRIN Inc.· Source

• Completed

  A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

  NCT05774184· Phase 2· Celldex Therapeutics· Source

• Active, not recruiting

  Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

  NCT05833438· Phase 2· University of Leipzig· Source

• Completed

  A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT05767021· Phase 3· Eli Lilly and Company· Source

• Completed

  A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

  NCT07304843· Phase 1/2· Umecrine Cognition AB· Source

• Completed

  A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

  NCT05811351· Phase 2· Janssen Research & Development, LLC· Source

• Active, not recruiting

  Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

  NCT05201066· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

  NCT05702034· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· Phase 3· Merck Healthcare KGaA· Source

• Active, not recruiting

  A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

  NCT05567796· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

  NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source

• Completed

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· Phase 3· Amgen Inc.· Source

• Terminated

  Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

  NCT05384249· Phase 2· ACELYRIN Inc.· Source

• Completed

  Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

  NCT04991935· Phase 3· Celgene· Source

Showing 50 of 89.

Conditions

Diseases this institution publishes on or runs trials for.

• Obesity114 works · 7 trials
• Aortic stenosis16 works · 0 trials
• Meningioma11 works · 0 trials
• Peripheral artery disease10 works · 3 trials